Post by icemandios on Aug 31, 2021 12:36:16 GMT
Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021
PR Newswire
MARLBOROUGH, Mass. , Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows:
Event: ESMO Virtual Congress 2021
Title: Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors
Authors: Benjamin Cuiffo, et al.
Abstract Number: #4154
Date: September 16-21, 2021
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here) .
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows:
Event: ESMO Virtual Congress 2021
Title: Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors
Authors: Benjamin Cuiffo, et al.
Abstract Number: #4154
Date: September 16-21, 2021
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here) .
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .